These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9793271)

  • 1. Long-term disappearance of previous chromosomal abnormalities in myelodysplastic syndromes treated with low dose cytosine arabinoside and granulocyte/macrophage-colony stimulating factor.
    Sastre JL; Ulibarrena C; Bustillo M; Suárez-Gago M; García-Torremocha MS; Vázquez MO
    Haematologica; 1998 Aug; 83(8):763-5. PubMed ID: 9793271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of granulocyte-macrophage colony stimulating factor on paroxysmal nocturnal hemoglobinuria: a case report.
    Webb DI; Bundtzen JL
    Alaska Med; 1993; 35(3):216-7, 224. PubMed ID: 8109693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of anemia in myelodysplastic syndromes with recombinant human erythropoietin].
    Rodríguez JN; Prados D; Martino ML; Muñiz R
    Sangre (Barc); 1993 Aug; 38(4):340-1. PubMed ID: 8235952
    [No Abstract]   [Full Text] [Related]  

  • 8. Response of refractory anemia to low-dose cytosine arabinoside.
    Gallo JH; Rozenberg MC
    Aust N Z J Med; 1986 Apr; 16(2):231-3. PubMed ID: 3463278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
    Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
    Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; de Witte T; Jacobs A; Visiani G; Fiere D; Sonneveld P; Labar B
    Infection; 1992; 20 Suppl 2():S116-23. PubMed ID: 1493935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Ferrara F; Leoni F; Pinto A; Mirto S; Morra E; Zagonel V; Mele G; Ciolli S; Magrin S; Montillo M
    Cancer; 1999 Nov; 86(10):2006-13. PubMed ID: 10570425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of myelodysplastic syndromes].
    Hotta T
    Rinsho Ketsueki; 1990 Apr; 31(4):416-30. PubMed ID: 1696325
    [No Abstract]   [Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?
    Musto P; Falcone A; Carotenuto M; Catalano L; Cennamo A; Rotoli B
    Blood; 1994 Sep; 84(5):1687-8. PubMed ID: 7520783
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
    Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
    Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.